Genovis AB (publ.) (GENO) - Total Assets
Based on the latest financial reports, Genovis AB (publ.) (GENO) holds total assets worth Skr377.93 Million SEK (≈ $40.67 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Genovis AB (publ.) (GENO) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Genovis AB (publ.) - Total Assets Trend (2008–2025)
This chart illustrates how Genovis AB (publ.)'s total assets have evolved over time, based on quarterly financial data. See Genovis AB (publ.) shareholders equity for net asset value and shareholders' equity analysis.
Genovis AB (publ.) - Asset Composition Analysis
Current Asset Composition (December 2025)
Genovis AB (publ.)'s total assets of Skr377.93 Million consist of 54.7% current assets and 45.3% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr163.19 Million | 43.2% |
| Accounts Receivable | Skr0.00 | 0.0% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr83.93 Million | 22.2% |
| Intangible Assets | Skr79.30 Million | 21.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2008–2025)
This chart illustrates how Genovis AB (publ.)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Genovis AB (publ.) (GENO) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Genovis AB (publ.)'s current assets represent 54.7% of total assets in 2025, an increase from 7.6% in 2008.
- Cash Position: Cash and equivalents constituted 43.2% of total assets in 2025, up from 1.2% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 20.0% of total assets, an increase from 2.0% in 2008.
- Asset Diversification: The largest asset category is cash and equivalents at 43.2% of total assets.
Genovis AB (publ.) Competitors by Total Assets
Key competitors of Genovis AB (publ.) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
USA | $472.67 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $506.75 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
Genovis AB (publ.) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.36 | 7.38 | 5.19 |
| Quick Ratio | 7.36 | 6.91 | 5.19 |
| Cash Ratio | 5.81 | 6.01 | 0.00 |
| Working Capital | Skr178.55 Million | Skr179.99 Million | Skr59.09 Million |
Genovis AB (publ.) - Advanced Valuation Insights
This section examines the relationship between Genovis AB (publ.)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.26 |
| Latest Market Cap to Assets Ratio | 0.36 |
| Asset Growth Rate (YoY) | 15.4% |
| Total Assets | Skr377.93 Million |
| Market Capitalization | $135.93 Million USD |
Valuation Analysis
Below Book Valuation: The market values Genovis AB (publ.)'s assets below their book value (0.36x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Genovis AB (publ.)'s assets grew by 15.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Genovis AB (publ.) (2008–2025)
The table below shows the annual total assets of Genovis AB (publ.) from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr377.93 Million ≈ $40.67 Million |
+15.43% |
| 2024-12-31 | Skr327.41 Million ≈ $35.23 Million |
+13.35% |
| 2023-12-31 | Skr288.86 Million ≈ $31.09 Million |
+91.91% |
| 2022-12-31 | Skr150.52 Million ≈ $16.20 Million |
+6.19% |
| 2021-12-31 | Skr141.75 Million ≈ $15.25 Million |
+32.91% |
| 2020-12-31 | Skr106.65 Million ≈ $11.48 Million |
+117.45% |
| 2019-12-31 | Skr49.04 Million ≈ $5.28 Million |
+29.65% |
| 2018-12-31 | Skr37.83 Million ≈ $4.07 Million |
+43.80% |
| 2017-12-31 | Skr26.31 Million ≈ $2.83 Million |
+20.38% |
| 2016-12-31 | Skr21.85 Million ≈ $2.35 Million |
+29.19% |
| 2015-12-31 | Skr16.91 Million ≈ $1.82 Million |
-13.54% |
| 2014-12-31 | Skr19.56 Million ≈ $2.11 Million |
-52.80% |
| 2013-12-31 | Skr41.45 Million ≈ $4.46 Million |
+128.26% |
| 2012-12-31 | Skr18.16 Million ≈ $1.95 Million |
-15.31% |
| 2011-12-31 | Skr21.44 Million ≈ $2.31 Million |
+20.34% |
| 2010-12-31 | Skr17.82 Million ≈ $1.92 Million |
+20.72% |
| 2009-12-31 | Skr14.76 Million ≈ $1.59 Million |
-1.73% |
| 2008-12-31 | Skr15.02 Million ≈ $1.62 Million |
-- |
About Genovis AB (publ.)
Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an… Read more